XML 42 R28.htm IDEA: XBRL DOCUMENT v2.4.0.8
3. Fair Value Measurement (Tables)
9 Months Ended
Sep. 30, 2013
Fair Value Disclosures [Abstract]  
Company's fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring and nonrecurring basis

    September 30, 2013  
    Level 1     Level 2     Level 3     Total  
Liabilities                                
Contingent consideration(1)   $     $     $ 10,662     $ 10,662   
Put right(2)                 9,482       9,482  
Total Liabilities   $     $     $ 20,144     $ 20,144  

 

    December 31, 2012  
    Level 1     Level 2     Level 3     Total  
Assets                                
Investments in TherapeuticsMD   $     $     $ 5,711     $ 5,711  
Total Assets   $     $     $ 5,711     $ 5,711  
Liabilities                                
Contingent consideration(1)   $     $     $ 10,962     $ 10,962  
Put right(2)                 3,365       3,365  
Total Liabilities   $     $     $ 14,327     $ 14,327  

Fair Value Measurements Using Significant Unobservable Inputs
Assets:   Investment in Therapeutics MD  
Beginning balance at January 1, 2013   $ 5,710,526  
Net realized and unrealized gains (losses)        
   Included in earnings (in other income)     3,605,263  
   Included in accumulated other comprehensive income (pre-tax) (1)     (4,710,526 )
Sale of Investment in TherapeuticsMD     (4,605,263 )
Ending balance at September 30, 2013   $  
         

 

Liabilities:  

Contingent 

Liability

Consideration

 
Beginning balance at January 1, 2013   $ 14,327,680  
Interest accretion of Cypress contingent consideration     505,000  
Change in fair value of Cypress contingent consideration     (805,000) )
Change in fair value of Cypress put right     6,116,489  
Ending balance at September 30, 2013   $ 20,144,169